Recombinant Cynomolgus Monkey B7-H2 Fc Chimera Protein, CF Summary
Product Specifications
Cynomolgus Monkey B7‑H2 (Asp19-Thr256) Accession # XP_005548618 | IEGRMD | Human IgG1 (Pro100-Lys330) |
N-terminus | C-terminus | |
Analysis
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
9900-B7
Formulation | Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. |
Reconstitution | Reconstitute at 500 μg/mL in PBS. |
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage: |
|
Scientific Data
When Recombinant Cynomolgus ICOS Fc Chimera (Catalog # 9736-CS) is coated at 0.5 µg/mL, Recombinant Cynomolgus B7-H2 Chimera (Catalog # 9900-B7) binds with an ED50 of 4-20 ng/mL.
2 μg/lane of Recombinant Cynomolgus Monkey B7‑H2 was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 75-87 kDa and 150-170 kDa, respectively.
Reconstitution Calculator
Background: B7-H2
B7-H2, also known as B7-related protein (B7RP1), ICOS Ligand, and CD275, is an approximately 60 kDa transmembrane glycoprotein in the B7 family of immune regulatory molecules (1). Cynomolgus B7-H2 is synthesized as a 306 amino acid (aa) precursor protein. Based on the similarity with human B7-H2, mature cynomolgus B7-H2 is predicted to consist of a 226 aa extracellular domain (ECD) with two immunoglobulin-like domains, a 21 aa transmembrane segment, and a 21 aa cytoplasmic domain. Within the ECD, cynomolgus B7-H2 shares 94%, 50%, and 54% aa sequence identity with human, mouse, and rat B7-H2, respectively. B7-H2 is expressed on antigen presenting cells such as B cells, macrophages, monocytes, and dendritic cells (2-6). B7-H2 binds to ICOS on activated T cells, leading to both positive and negative effects on immune responses including its own down-regulation (2, 4, 7). Mouse and human B7-H2 exhibit cross-species binding to ICOS (3, 6). The B7-H2 interaction with ICOS is co-stimulatory for T cell proliferation as well as the development of B cells, plasma cells, follicular helper T cells (Tfh) and germinal centers (2-4, 8, 9). In human but not in mouse, B7-H2 additionally binds to CD28 and CTLA4, and its interaction with CD28 can co-stimulate both human and mouse naïve T cells and regulatory T cells (Treg) (6). B7-H2 contributes to the development of allergic asthma by enhancing Th2 biased immune responses, limiting Th17 responses, and promoting eosinophilic infiltration into the lung (8, 10, 11). Its activation of ICOS on Treg limits pulmonary inflammation and airway hyperresponsiveness, promotes the development of inhalational tolerance, and impairs anti-tumor immunity (5, 12, 13). In contrast, its ligation of ICOS on Tfh cells can increase the severity of autoimmune symptoms (9). A soluble form of human B7-H2 is elevated in the circulation of patients with active systemic lupus erythematosus (14). In the thyroid, B7-H2 is up-regulated on thyrocytes during inflammation and promotes their proliferation and production of thryoid hormones (15). B7-H2 and ICOS expressed on ILC2 cells. B7-H2/ICOS interaction promoted cytokine production and survival in ILC2 cells through STAT5, suggesting that B7-H2/ICOS signaling pathway is critically involved in ILC2 function and homeostasis (16).
- Bour-Jordan, H. et al. (2011) Immunol. Rev. 241:180.
- Wang, S. et al. (2000) Blood 96:2808.
- Yoshinaga, S.K. et al. (2000) Int. Immunol. 12:1439.
- Yoshinaga, S.K. et al. (1999) Nature 402:827.
- Faget, J. et al. (2012) Cancer Res. 72:6130.
- Yao, S. et al. (2011) Immunity 32:729.
- Watanabe, M. et al. (2008) J. Immunol. 180:5222.
- Wong, S.-C. et al. (2003) Blood 102:1381.
- Hu, Y.-L. et al. (2009) J. Immunol. 182:1421.
- Kadkhoda, K. et al. (2010) J. Immunol. 184:3780.
- Kadkhoda, K. et al. (2011) Int. Immunol. 23:239.
- Gajewska, B.U. et al. (2005) J. Immunol. 174:3000.
- Akbari, O. et al. (2002) Nat. Med. 8:1024.
- Her, M. et al. (2009) Lupus 18:501.
- Wang, F. et al. (2012) J. Clin. Immunol. 32:1253.
- Maazi H. et al. (2015) Immunity.42:538.
FAQs
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsReviews for Recombinant Cynomolgus Monkey B7-H2 Fc Chimera Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Cynomolgus Monkey B7-H2 Fc Chimera Protein, CF and earn rewards!
Have you used Recombinant Cynomolgus Monkey B7-H2 Fc Chimera Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image